source
- Experts tout amylin as promising, potentially gentler obesity target as new combo therapies near FDA reviewWhile GLP-1 medicines dominate the weight‑loss market, some observers argue that amylin would have been the logical primary target for obesity treatment a decade ago. Novo Nordisk’s amylin/GLP‑1 c…
- Massachusetts jury awards former MIT professor David Sabatini $6 million in defamation caseA Massachusetts jury has ordered a $6 million damages award to David Sabatini, a former professor at MIT and noted biologist. The verdict stems from a defamation lawsuit that Sabatini filed after…